Prosecution Insights
Last updated: October 02, 2026
Application No. 18/232,238

HUMAN ANTIBODIES TO BET V 1 AND METHODS OF USE THEREOF

Non-Final OA §DOUBLEPATENT
Filed
Aug 09, 2023
Priority
Jun 01, 2017 — provisional 62/513,872 +4 more
Examiner
ROONEY, NORA MAUREEN
Art Unit
1641
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Regeneron Pharmaceuticals Inc.
OA Round
3 (Non-Final)
60%
Grant Probability
Moderate
3-4
OA Rounds
4m
Est. Remaining
84%
With Interview

Examiner Intelligence

Grants 60% of resolved cases
60%
Career Allowance Rate
451 granted / 748 resolved
At TC average
Strong +24% interview lift
Without
With
+23.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
38 currently pending
Career history
780
Total Applications
across all art units

Statute-Specific Performance

§101
7.8%
-32.2% vs TC avg
§103
21.7%
-18.3% vs TC avg
§102
20.6%
-19.4% vs TC avg
§112
35.7%
-4.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 748 resolved cases

Office Action

§DOUBLEPATENT
Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . 2. Applicant is advised that the Notice of Allowance mailed 03/02/2026 is vacated. If the issue fee has already been paid, applicant may request a refund or request that the fee be credited to a deposit account. However, applicant may wait until the application is either found allowable or held abandoned. If allowed, upon receipt of a new Notice of Allowance, applicant may request that the previously submitted issue fee be applied. If abandoned, applicant may request refund or credit to a specified Deposit Account. 3. The information disclosure statements (IDS) submitted on 04/22/2026 and 05/04/2026 were filed after the mailing date of the Notice of Allowance on 03/02/2026. The submissions are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner. 4. Prosecution on the merits of this application is reopened on claims 42, 62, 64-69, 76, 78-83, 90 and 92-105 considered unpatentable for the reasons indicated below: 5. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. 6. Claims 42, 62, 64-69, 76, 78-83, 90 and 92-105 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-47 of U.S. Patent No. 12,583,914 (IDS filed on 04/22/2026). Although the claims at issue are not identical, they are not patentably distinct from each other because claims 1-47 of U.S. Patent No. 12,583,914 are directed to antibodies comprising reference SEQ ID NOs 1 and 5 (which are 100% identical to instant SEQ ID NOs 146 and 154); reference SEQ ID NOs 21 and 25 (which are 100% identical to instant SEQ ID NOs 290 and 298); and reference SEQ ID NOs11 and 15 (which are 1005 sequence identical to instant SEQ ID NOs 98 and 106). The claimed invention differs from the prior art in the recitation of a nucleic acid encoding the antibodies; an expression vector comprising the nucleic acid encoding the antibodies; a host cell comprising the expression vector comprising the nucleic acid encoding the antibodies; and a method of producing the antibodies of claims 42, 62, 64-69, 76, 78-83, 90 and 92-105. From the combined teachings of the reference, it is apparent that one of ordinary skill in the art would have had a reasonable expectation of success in producing the claimed invention. Therefore, the invention as a whole was prima facie obvious to one of ordinary skill in the art at the time the invention was made, as evidenced by the references, especially in the absence of evidence to the contrary. 7. No claim is allowed. 8. Any inquiry concerning this communication or earlier communications from the examiner should be directed to NORA MAUREEN ROONEY whose telephone number is (571)272-9937. The examiner can normally be reached on M-F from 8:00am to 4:30pm. If attempts to reach the examiner by telephone are unsuccessful, the examiner' s supervisor, Misook Yu, can be reached at telephone number (571) 272-0839. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from Patent Center. Status information for published applications may be obtained from Patent Center. Status information for unpublished applications is available through Patent Center for authorized users only. Should you have questions about access to Patent Center, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) Form at https://www.uspto.gov/patents/uspto-automated- interview-request-air-form. August 13, 2026 /Nora M Rooney/ Primary Examiner, Art Unit 1641
Read full office action

Prosecution Timeline

Aug 09, 2023
Application Filed
Nov 27, 2023
Response after Non-Final Action
Apr 24, 2025
Non-Final Rejection mailed — §DOUBLEPATENT
Jul 24, 2025
Response Filed
Nov 05, 2025
Final Rejection mailed — §DOUBLEPATENT
Jan 05, 2026
Response after Non-Final Action
Feb 16, 2026
Response after Non-Final Action
Aug 18, 2026
Non-Final Rejection mailed — §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12747287
Methods Of Identifying And Evaluating Cat Allergy Gene Signatures In A Subject By Determining A Stratified Score Based On Gene Expression
3y 3m to grant Granted Sep 29, 2026
Patent 12715935
METHODS AND COMPOSITIONS FOR INDUCIBLE EXTRACELLULAR MEMBRANE CAPTURE OF MONOCLONAL IMMUNOGLOBULINS SECRETED BY HYBRIDOMAS
2y 6m to grant Granted Aug 25, 2026
Patent 12702642
COMPOSITION AND METHOD FOR REDUCING ALLERGIC RESPONSE
3y 5m to grant Granted Aug 11, 2026
Patent 12662552
ANTIBODY FOR NEUTRALIZING SUBSTANCE HAVING COAGULATION FACTOR VIII (F.VIII) FUNCTION-SUBSTITUTING ACTIVITY
3y 7m to grant Granted Jun 23, 2026
Patent 12655205
ANTIBODIES AND ASSAYS FOR CCL14
2y 5m to grant Granted Jun 16, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
60%
Grant Probability
84%
With Interview (+23.6%)
3y 5m (~4m remaining)
Median Time to Grant
High
PTA Risk
Based on 748 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month